Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib or Enasidenib + Chemotherapy in Newly Diagnosed AML or MDS-EB2
NCT03839771Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Mar 2019
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of ivosidenib and enasidenib in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts-2 (MDS-EB-2), sponsored by HOVON. Primary endpoint: Event-free survival at 60 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)
Beyond the preview
Go deeper on NCT03839771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839771.